openPR Logo
Press release

Serotonin Acquires Unparalleled to Create 1m+ EBITDA Marketing Powerhouse

08-06-2025 08:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: BrandingBuzz.Agency
Serotonin Acquires Unparalleled to Create 1m+ EBITDA Marketing

Acquisition marks the launch of Serotonin's buy-and-build strategy to consolidate digital marketing services at scale.
Image: https://www.globalnewslines.com/uploads/2025/08/281952c2eb2b091e8b4ac31ab1bb3267.jpg

Manchester, UK - Serotonin [https://www.serotonin.co.uk/] (www.serotonin.co.uk) has officially acquired Unparalleled, a digital agency known for its expertise in ecommerce and performance marketing.

The move creates a new force in the North West's marketing scene, with combined operations now generating in excess of 1 million in EBITDA annually. Unparalleled brings a team of 12 experts across to Serotonin increasing the total headcount within the agency to 32, with a plan to grow that to 40 by the end of 2025.

Serotonin selected Unparalleled for acquisition due to the agency's unique expertise in performance media and its proven ability to deliver exceptional ROI through advanced tools and data-led strategy. The company now plans to raise its first institutional funding round in Q1 2025 to accelerate growth and execute a targeted series of strategic acquisitions.

For Serotonin, known for working with large ecommerce clients like ASSOS of Switzerland, New & Lingwood and national property developers such as Legal & General and Grainger plc; this acquisition marks the beginning of a wider buy-and-build strategy aimed at consolidating best-in-class service providers under one roof.

Unparalleled brings deep expertise in ecommerce growth, having worked with high-performance brands such as The Private Clinic and Ebrands. Their strength in Google and Meta media buying, combined with their ability to leverage new technologies, significantly enhances Serotonin's paid media and digital strategy capabilities.

"This is a deliberate step forward in building a high-performance agency group, one that brings together specialist talent under a shared vision for performance, creativity and results. The acquisition of Unparalleled further strengthens our position in a fragmented market, forecasts our EBITDA for 2025 at over 1mln, and expands our capabilities where it counts. Serotonin was already a serious player, now we're moving faster, going bigger, and focussed on scaling through smart, strategic moves." - Dom Carter [https://www.linkedin.com/in/djvcarter], CEO Serotonin

"The core principle behind Unparalleled was to provide high-growth brands with a strategic advantage through more intelligent and profitable marketing. Integrating with Serotonin allows us to apply this vision on a grander scale. This acquisition marks the creation of a new agency model-one built for agility, strategic acquisitions, and optimised for rapid growth." - Luke Bielby [https://www.linkedin.com/in/lukebielby/], Former CEO Unparalleled, Chief Commercial Officer Serotonin

Serotonin was expertly advised by leading corporate law firm Pannone Corporate LLP, whose strategic legal guidance was instrumental to the successful completion of the transaction.

About Serotonin

Serotonin is a full-service agency for global businesses that want to grow better, faster. Founded by Dom Carter and Clair Heaviside in 2019, Serotonin partners with ambitious brands to scale ecommerce channels through paid media, data strategy, and creative excellence.

From its Manchester studio, Serotonin supports clients across the UK, Europe, and the US. Notable clients include: ASSOS of Switzerland, British Cycling, Blacklock, New & Lingwood, Belier, and SUDU.

Serotonin were listed in The Prolific North Top 50 Digital Agencies 2025 and have previously won Best Mid-Size Agency and Best Small Agency awards. Co-founder Clair Heaviside was named Businesswoman of the Year in 2023, one of NatWest's Top Ten Female Entrepreneurs to Watch and Northern Gamechanger in 2025. CEO Dom Carter was listed as Tech Pioneer in the BIMA 100 and named Digital, Media & Creative Professional of the Year by Manchester Young Talent Awards, and Young Marketing & Media Professional 2022 by Insider Media

To find out more, contact Dom directly at dom@serotonin.co.uk or visit serotonin.co.uk [https://serotonin.co.uk/]
Media Contact
Company Name: Serotonin
Contact Person: Dom Carter
Email: Send Email [http://www.universalpressrelease.com/?pr=serotonin-acquires-unparalleled-to-create-1m-ebitda-marketing-powerhouse]
Phone: 07805897192
Address:25 Dale Street, 5th Floor, Manchester
City: Greater Manchester, M1 1EY
State: GB
Country: United Kingdom
Website: https://www.serotonin.co.uk/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Serotonin Acquires Unparalleled to Create 1m+ EBITDA Marketing Powerhouse here

News-ID: 4135970 • Views:

More Releases from Getnews

Mountainside The Leader in Kratom Treatment Reports A Surge in Kratom Detox Admissions Amid Growing National Concern
Mountainside The Leader in Kratom Treatment Reports A Surge in Kratom Detox Admi …
Image: https://www.globalnewslines.com/uploads/2025/10/4533860af418fc8017eaceaaf1925194.jpg CANAAN, CT - Mountainside Treatment Center's Detox Program is experiencing a notable rise in kratom-related admissions as lawmakers and public health officials nationwide intensify scrutiny of the unregulated substance and its potent derivative, 7-hydroxymitragynine (7-OH). Following Florida's statewide ban on 7-OH and pending Connecticut legislation (HB 6855), Mountainside has seen increased engagement across multiple levels of care. While Jana Wu's [https://www.mountainside.com/people/jana-wu/] weekly virtual Kratom Support Group [https://www.mountainside.com/resources/support-groups/virtual/ltk-support-group/] continues to attract new
Marine Toys for Tots, in Collaboration with Hasbro and Colossal, Proudly Announces the 2025 Toddler of the Year
Marine Toys for Tots, in Collaboration with Hasbro and Colossal, Proudly Announc …
Image: https://www.globalnewslines.com/uploads/2025/10/1760034821.jpg "Thanks to Hasbro and Colossal, the Toddler of the Year campaign became a nationwide celebration of imagination and pure childhood wonder. Every tot nominated is a reminder that the future is bright and brimming with possibility." - LtGen Laster This spirit has shone bright in the Toddler of the Year campaign, a nationwide competition hosted by Mario Lopez-in partnership with Marine Toys for Tots, Hasbro, and Colossal-where one extraordinary tot
Award-Winning Songwriter Brings Joy to Halloween with New Tune,
Award-Winning Songwriter Brings Joy to Halloween with New Tune, "Octagooney" and …
Award-Winning Songwriter Brings Joy to Halloween with New Tune, "Octagooney," and Kindness for Kids Songs Tricia Greenwood, creator of the Kindness for Kids Club, releases her latest story-song "Octagooney" alongside children's favorites now streaming on iTunes, YouTube, and Spotify. This Halloween, award-winning singer-songwriter Tricia Greenwood brings families a fresh reason to smile with her new story-song and children's book, Octagooney. The playful tune introduces a lovable, eight-armed pumpkin hero who lights up
RankWorks Launches Unified AI Marketing Platform to Simplify Markeing for SMBs
RankWorks Launches Unified AI Marketing Platform to Simplify Markeing for SMBs
Montreal, QC - October 14, 2025 - RankWorks has launched a unified AI marketing platform to help small and medium-sized enterprises (SMEs) and lean marketing teams manage their entire online visibility stack from a single login. The platform brings together SEO, content marketing, social media, reputation management, and analytics to eliminate the need for multiple disconnected tools that often overwhelm business owners and strain limited resources. Image: https://www.globalnewslines.com/uploads/2025/10/840e6ffea38a97cff9c5bf969069adb2.jpg For many small business

All 5 Releases


More Releases for Serotonin

Serotonin Supplement Market is on an Upward Growth Curve
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Serotonin Supplement Market- (By Functionality (Depression Relief, Insomnia Relief, Appetite Gaining, Mood Disorder Treatment, Weight Loss, and Cognitive Health Improvement), By Form (Tablets / Pills, Capsules, Liquid, Powder/ Chewable and Others), By Sales Channel (Hypermarkets / Supermarkets, Specialty Stores, E-commerce, Drug Stores & Pharmacies, Health & Wellness Stores, Convenience Stores, Departmental Stores and Others), By
Serotonin Supplement Market Know the Scope and Trends
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Serotonin Supplement Market- (By Functionality (Depression Relief, Insomnia Relief, Appetite Gaining, Mood Disorder Treatment, Weight Loss, and Cognitive Health Improvement), By Form (Tablets / Pills, Capsules, Liquid, Powder/ Chewable and Others), By Sales Channel (Hypermarkets / Supermarkets, Specialty Stores, E-commerce, Drug Stores & Pharmacies, Health & Wellness Stores, Convenience Stores, Departmental Stores and Others), By
Global Antidepressants Drugs Market Size - By Product Type(Tricyclic Antidepress …
Antidepressants Drugs Market Insights: Trends, Drivers, and Outlook 2024 - 2031 Antidepressants Drugs Market Scope: Unveiling Today's Trends Antidepressant drugs are medications designed to alleviate symptoms of depression and mood disorders. The global antidepressants market has been witnessing significant growth, driven by increasing awareness and diagnosis of mental health issues, along with a rising prevalence of depression and anxiety disorders. As healthcare systems prioritize mental health, the demand for effective pharmacological treatments
Serotonin-Dopamine Activity Modulators Market Insights, Forecast to 2031
The report extensively examines the global Serotonin-Dopamine Activity Modulators market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Serotonin-Dopamine Activity Modulators . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the
Global Serotonin Syndrome Market Size, Status and Forecast 2019-2025
Market Research Report Store offers a latest published report on Serotonin Syndrome Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 158 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/632687/global-serotonin-syndrome-market-size-status   Serotonin syndrome is a group of symptoms
04-06-2017 | Health & Medicine
TMR
Global Serotonin-norepinephrine Reuptake Inhibitors Market Future Outlook 2024
Serotonin-norepinephrine reuptake inhibitors (SNRIs) or dual - uptake inhibitors represent one of the newest but important classes of antidepressants, which are commonly prescribed for anxiety disorders and depression therapeutic treatment. SNRIs were first launched in the international markets in 1993, when the U.S. FDA approved first of its kind Venlafaxine (Effexor) as an antidepressant, which would help treat numerous individuals suffering from varying anxiety disorders and/or depression. Browse Market Research Report